@Article{,
AUTHOR = {Gerald H. Jordan},
TITLE = {Peyronie’s disease: update on medical management and surgical tips},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {14},
YEAR = {2007},
NUMBER = {Suppl.6},
PAGES = {69--74},
URL = {http://www.techscience.com/CJU/v14nSuppl.6/63324},
ISSN = {1488-5581},
ABSTRACT = {Peyronie's disease is a scarring phenomenon of the penis
causing various deformities; initially pain with erection,
and in most patients is associated with some element of
erectile dysfunction. Studies of the natural history of
the disease show that Peyronie's disease is a self-limited
condition. In its stable and quiescent phase, patients have
stable deformity, and in some cases that deformity then
requires surgery.<br/>
For the most part, pharmacologic therapy is confined to
the immature or active phase of the disease.
Pharmacotherapy is aimed at trying to adjust or interfere
with the scarring process, so that the resultant scar causes
as little disability as possible to the patient. Most
pharmacotherapy is thus useful only in the active/
immature phase of disease. In the mature or quiescent
phase of the disease, therapy is aimed at undoing the
effects of the scarring lesion. Those therapies for the most
part can be considered “scar revisions”. There is no best
surgical therapy, and unfortunately because the disease
process generally evolves with the background of erectile
dysfunction, often times with surgery there is progression
of the erectile dysfunction. All patients should be
counseled with regards to the option of continued
watchful waiting. Patients who are operated on must be
counseled with regards to realistic outcomes.},
DOI = {}
}